INSUBCONTINENT EXCLUSIVE:
NEW DELHI: Shares of pharmaceutical firm Wockhardt climbed over 2 per cent in early trade on Monday.
Shares of the company got tractions
after it said that the USFDA's inspection of its Bioequivalence centre in Aurangabad, Maharashtra yielded no observations.
In a regulatory
filing, the company said no observations were made after the US drug regulator inspected its Bioequivalence centre during which
Bioequivalence studies of Tamsulosin 0.4mg capsules and Metoprolol Tartrate 200mg ER tablets were audited.
"At the end of inspection, there
zero 483 observation), signifying that best practices were followed, in compliance to applicable regulations
This outcome would lead approvals of ANDAs in pipeline for which Bioequivalence studies are being or will be done in the said Centre," the
company said.
Shares of the company traded 1 per cent up at Rs 453.75 apiece around 10:15 am on BSE.
